Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Kalshi and Polymarket, two prediction markets, began offering bets on clinical trial outcomes for pharmaceutical drugs. Researchers raised concerns that such betting could create incentives for insider trading and potentially interfere with drug development timelines. The platforms stated that their markets provide information to patients about drug prospects. The clinical trial betting markets became available in 2025 and generated debate among medical professionals and market regulators about their potential effects on drug testing integrity.

Next story